GlassScriptPhysician profile
David D Nisley
NPI 1710044888
$4,432.43
in general payments reported to CMS, 2019-2025
22 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $236 · 2022: $169 · 2023: $216 · 2024: $3,564 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,510 · Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,509.90 |
| Food and Beverage | $518.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,547.70 | 2021-2024 | |
| Abbvie INC. | $185.74 | 2021-2023 | |
| Currax Pharmaceuticals LLC | $92.99 | 2023-2025 | Contrave, Nexletol, Nexlizet |
| Globus Medical, INC. | $72.30 | 2025 | Senza |
| Novo Nordisk INC | $62.73 | 2021-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $60.18 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $51.07 | 2021-2023 | Trintellix |
| Axsome Therapeutics, INC. | $49.22 | 2023 | Sunosi |
| Amgen INC. | $37.01 | 2021 | |
| Nevro Corp. | $36.91 | 2024 | Senza |
| Otsuka America Pharmaceutical, INC. | $36.34 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $28.10 | 2021 | |
| Glaxosmithkline, LLC. | $23.21 | 2025 | Arexvy, Shingrix |
| Avanir Pharmaceuticals, INC. | $21.77 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.73 | 2023 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $16.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.67 | 2022 | |
| Lundbeck LLC | $16.52 | 2025 | Rexulti |
| Acella Pharmaceuticals, LLC | $15.06 | 2025 | NP Thyroid 60 |
| Bayer Healthcare Pharmaceuticals INC. | $14.82 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.63 | 2022 | |
| Astellas Pharma US INC | $12.85 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nisley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.